ArticleFrontiers in immunology2022

Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell.

Rui Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.